In vitro evaluation of selligueain A effects on the pro-inflammatory mediators production in RAW264.7 murine macrophages

Deden Winda Suwandi1,2, Tina Rostinawati1, Muchtaridi Muchtaridi3, Anas Subarnas1*

1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia
2Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Garut, Garut, Indonesia
3Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia
4Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Sumedang, Indonesia

*Corresponding author: Anas Subarnas, Email aasubarnas@yahoo.co.id

Introduction: Selligueain A derived from the roots of Polypodium feei was shown to have anti-inflammatory activity, which was tested in vivo on the rats’ paw edema induced by carrageenan. The aim of this study was to evaluate the anti-inflammatory mechanism of selligueain A in vitro against the production of pro-inflammatory mediators.

Methods: In this study, RAW264.7 cells were used as an inflammatory cell model, and observations were made on the inflammatory mediators nitric oxide (NO), inducible nitric oxide synthase (iNOS), and tumour necrosis factor-α (TNF-α). The NO concentration was measured by the Griess reaction, and the iNOS enzyme and the TNF-α concentrations were determined by the ELISA method. Cell viability was assessed by the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) test.

Results: Selligueain A at concentrations of 100 and 150 µM suppressed the production of NO, iNOS, and TNF-α in RAW264.7 cells stimulated by lipopolysaccharide (LPS). The concentration of 150 µM showed the highest inhibition of NO, iNOS, and TNF-α mediators with the percentage inhibition of 64.85, 55.01, and 48.54%, respectively.

Conclusion: This study shows that selligueain A has anti-inflammatory activity through inhibition of NO, iNOS, and TNF-α production in RAW264.7 macrophage cells.

Implication for health policy/practice/research/medical education: Selligueain A of the P. feei roots had anti-inflammatory activity through the inhibition of the production of inflammatory mediators, NO, iNOS, and TNF-α. The results will encourage further researches to complement scientific evidence regarding the efficacy of Selligueain A, as an anti-inflammatory agent.

Please cite this paper as: Suwandi DW, Rostinawati T, Muchtaridi M, Subarnas A. In vitro evaluation of selligueain A effects on the pro-inflammatory mediators production in RAW264.7 murine macrophages. J Herbmed Pharmacol. 2021;10(3):313-318. doi: 10.34172/jhp.2021.36.
processes of inflammation. TNF-α is a cytokine that signals an inflammatory response. Inhibition of inflammation is an important target to prevent the occurrence of diseases in the body, especially diseases mediated by inflammation such as cancer, diabetes mellitus, neurological disease, autoimmune disease, and arthritis (1). One of the most common inflammatory diseases in the world is arthritis, which is characterized by pain, swelling and stiffness in the joints (3).

Polypodium feei METT., (synonym: Selliguela feeli) is a plant of the genus of Polypodium in the Polypodiaceae family. This genus is widely spread throughout the world, with the highest species diversity in the tropics. P. feei is a fern plant that grows in forests, in open areas, among rocks, mostly at 900-3150 m altitude. In the Java islands, it grows especially on volcanoes, near craters, because it is resistant to volcanic fumes, and occurs in abundance around the crater of the Tangkuban Perahu mountain in West Java of Indonesia (4).

In traditional medicine, the roots or rhizomes of P. feei are commonly used to facilitate urination, treat rheumatism, lower blood pressure, or exert an aphrodisiac effect. Baek et al reported a trimeric proanthocyanidin constituent of the P. feei roots, named selligueain A, which was rated highly sweet by a taste panel and not toxic for mice in the preliminary acute toxicity test. In our previous study, selligueain A showed analgesic and anti-inflammatory activities in mice and rats. Also, its proanthocyanidin fraction inhibited COX activity (4). The molecular docking proved that proanthocyanidin afzelechin (a monomer of selligueain A) could interact with Met522 of Cox-1 and 2 by the hydrogen binding (5).

The aim of this study was to evaluate anti-inflammatory mechanism of action of selligueain A isolated from the P. feei roots against the RAW264.7 cells stimulated by lipopolysaccharide (LPS). The macrophage RAW264.7 cells of LPS-stimulated mice were used as an inflammatory cell model.

Materials and Methods

Materials

Selligueain A was isolated from the P. feei roots. Aquabidest, Dulbecco’s modified Eagle’s medium/DMEM (Biowest®), 10% fetal bovine serum/FBS (Biowest®), 1% antibiotic and antimitotic/ABAM (Biowest®), sel RAW 264.7 (ATCC®TIB-71), mouse TNF-α ELISA kit (ElabScience®), mouse NOS2/iNOS ELISA Kit (ElabScience®), Kit NO assay (ElabScience®), micropipette (Finnpipette™ F2), spectrophotometer (GO Thermo Scientific®), vortex (Wisemix®), Tips Blue, yellow, white (Neptune Scientific®), and microtube 1.5 mL (SPL) were used in this study.

Extraction and isolation of selligueain A

The dried powders of the P. feei roots (4.5 kg) were extracted with methanol by a maceration method at room temperature. The extraction was carried out three times and each time of extraction was for 24 hours. The methanol extract was concentrated by evaporation of the solvent under lower pressure at the temperature of 50°C to get a concentrated extract (1232.7 g).

The extract was fractionated by partitioning method using the n-hexane-water (3:1) and ethyl acetate-water (3:1) mixture successively to give the fractions of n-hexane, ethyl acetate, and water (60.12, 513.75, and 298.6 g, respectively). Based on our previous work (4), the targeted selligueain A compound was contained in the ethyl acetate fraction, so isolation work was conducted on the ethyl acetate fraction. The ethyl acetate fraction was column chromatographed using the mixture of n-hexane, ethyl acetate, and methanol as a mobile phase and silica gel 60 as a stationary phase to give 10 fractions. The fraction 6 that was predicted to contain selligueain A was further subjected to column chromatography using the mixture of chloroform-methanol (10:0, 9:1, 8:2, 7:3, and 6:4) as eluent to obtain the selligueain A. The spectroscopic spectral data (UV, IR, MS, and NMR) of the isolated compound were analysed to identify the compound which was confirmed by comparison of its data with those reported in the literature (6).

Cell culture

RAW264.7 cells of a murine macrophage were cultured in DMEM supplemented in 10% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin. Cells were grown to a confluence of 80%–90% and applied to no more than 20 cell passages, afterward the cells were acclimatized for 12 hours before any use (7).

Measurement of RAW264.7 cell viability

Cell viability was determined by MTS assay. About 80%–90% of confluent cells were discarded and washed with PBS 1x. PBS for rinsing was removed and added 1 mL of Trypsin-EDTA 0.25%. The mixture was incubated at 37°C for 3 minutes, so that the cells were detached from the bottom of the flask. Checking was done using an inverted microscope to ensure that the cells have been completely detached from the bottom of the flask. Two mL of complete growth medium was added to stop the trypsinization process. The cells were put into a 15 mL centrifuge tube and centrifuged at 1600 rpm for 5 minutes. The supernatant was removed, and the pellet was resuspended with 1 mL growth medium. Cell resuspension was calculated using haemocytometer. After knowing the number of cells at 1 mL of previous cell resuspension, 5×10⁴ cells/well cells were planted on a 96 well plate. The cells were incubated at 37°C, 5% CO₂ to 80%–90% confluent cells. If it was confluent, the samples at various doses (200, 150, 100, 50, 25, 12.5, and 6.25 µM) were given and then incubated at 37°C, 5% CO₂ for 24 hours. After a 24 hours treatment, 20 µL MTS was added, and incubated for 3 hours at 37°C, 5%
CO₂. The absorbance was recorded at a wavelength of 490 nm, and optical densities were determined at 490 nm by means of a microplate reader (8).

Measurement of NO
The RAW264.7 cells were seeded in 96-well plates (2 × 10³ cells/mL) and incubated at 37°C in a humidified atmosphere with 5% CO₂. Twelve hours after treatment, the cells were treated with various concentrations of selligueain A (10, 100, and 150 µM) for 1 hour and afterward LPS (1 µg/mL) was added for 24 hours. Before heading to the NO test reaction, pre-treatment was carried out. In the standard and sample tubes, various concentrations of Sodium Nitrite Standard were added (To 150 µL was added 200 µL reagent 1 and 100 µL reagent 2). All reagents were mixed and incubated for 15 minutes at room temperature, then centrifuged (3100 g, 10 minutes). A total of 160 µL supernatant was inserted in 96 wells-plates and added 80 µL chromogenic reagent. All reagents in the well were shaken for 2 minutes and incubated for 15 minutes at room temperature. The NO test results were read at OD 550 nm (9).

Determination of TNF-α by ELISA
TNF-α level in each sample was determined using a commercially available ELISA kit, and assays were conducted in accordance with the manufacturer’s instructions. Briefly, the cells were cultured in 24-well plates (5 × 10⁴ cell/mL) for 12 hours, pre-incubated for 1 hour with various concentrations of selligueain A, and stimulated with LPS (1 µg/mL) for 24 hours. Cell culture supernatants obtained were immediately quantified by means of ELISA kits based on the manufacturer’s instructions. The standard solution was placed in each well twice as much as 100 µL, covered with a seal, and incubated for 90 minutes at 37°C. The plate was washed five times. Then, 90 µL/well substrate was added and incubated for 15 minutes at 37°C. If the colour was not changed, incubation time was added but not until 30 minutes. The 50 µL/well stop solution was added to each well. OD was measured at 450 nm using a spectrophotometer (11).

Statistical analysis
Data were analysed by one-way analysis of variance (ANOVA) and continued by a post hoc least-significant difference test. The data are presented as mean ± standard deviation. A P value of less than 0.05 was considered significantly different.

Results
Identification of selligueain A
Selligueain A is a known compound of the P. fcei roots. The identification of this compound was just conducted by analyzing its spectroscopic spectral data (UV, IR, MS, and NMR) and comparing its data with those reported in the literature (6). Its structure is shown in Figure 1.

In vitro examination of the anti-inflammatory property of Selligueain A
An examination of selligueain A against the production of pro-inflammatory mediators on RAW 264.7 makrofag cells was initially conducted by determining cell viability, followed by measuring the NO, TNF, and iNOS levels.

Determinant of iNOS by ELISA
iNOS level in each sample was measured using a commercially available ELISA kit, and assays were carried out based on the manufacturer’s instructions. Briefly, the cells were cultured in 24-well plates for 12 hours, pre-incubated for 1 hour with various concentrations of selligueain A, then stimulated with LPS (1 µg/mL) for 24 hours. Cell culture supernatants were collected and immediately quantified using ELISA kits in accordance with the manufacturer’s instructions. The standard solution was placed in each well twice as much as 100 µL, then covered with a seal, and incubated for 90 minutes at 37°C. Next, the solution was discarded and a Biotinylated Detection Absolution of 100 µL/well was immediately added, covered, and incubated for 1 hour at 37°C. The solution was discarded and washed with Wash Buffer, then waited for 1-2 minutes and discarded-repeated three times. After cleaning, 100 µL/well HRP conjugate was added, and the plate was covered and incubated for 30 minutes at 37°C. The plate was washed five times. Then, 90 µL/well substrate was added and incubated for 15 minutes at 37°C. The absorbance was recorded at OD 550 nm using a spectrophotometer (11).

Figure 1. Structure of selligueain A.
Measurement of RAW264.7 cell viability
The data of the RAW264.7 cell viability measurement are shown in Figure 2. Selligueain A did not cause cell death at any concentration used (6.25, 12.5, 25, 50, 100, 150, and 200 µM) on RAW264.7 cells.

Inhibition of NO release from LPS-stimulated RAW264.7 cells
Inhibition of selligueain A against NO release from LPS-stimulated RAW264.7 cells is shown in Figure 3. Selligueain A at the concentrations of 100 dan 150 µM decreased NO levels significantly as compared to the control (P<0.05). The percentage inhibition of each concentration (10, 100, and 150 µM) showed a concentration-dependent manner (28.43, 57.30, and 64.85%, respectively).

Inhibition of iNOS enzyme in RAW264.7 cells
Selligueain A was examined for its inhibition on the synthesis of iNOS enzyme, which is responsible as a provider and synthesizer of NO inflammatory mediators. The iNOS enzyme is a physiological element that can initiate inflammation. Selligueain A at the concentrations of 100 dan 150 µM decreased iNOS levels significantly as compared to the control (P<0.05) (Figure 4). The percentage inhibition of each concentration (10, 100, and 150 µM) showed a concentration-dependent manner (26.35, 30.89 and 55.01%, respectively).

Inhibition of TNF production in LPS-stimulated RAW264.7 cells
The inhibition of selligueain A against TNF-α production in LPS-RAW264.7 cells is shown in Figure 5. Among the examined concentrations (10, 100, and 150 µM), the concentration of 150 µM decreased TNF-α production significantly as compared to the control (P<0.05). The percentage inhibition of each concentration was 11.41, 27.78, and 48.54%.

Discussion
The evaluation of anti-inflammation of a test compound in vitro could be conducted by examining its inhibitory
activity against the inflammatory mediator production, such as NO, iNOS, and TNF-α on RAW 264.7 cells induced by LPS. The existence of macrophage cells in the inflammatory process is one of the cellular responses that play a role in body defense. Macrophages participate in initiating the inflammatory response during inflammation. The process involves the production of inflammatory mediators such as cytokines TNF-α, interleukins, prostaglandins, NO, and the enzymes such as COX and iNOS. These enzymes are useful in protecting the body from the infection or tissue damage (1,12). These mediators have an important role in the pathogenesis of acute and chronic inflammation (13). The production of cytokines and pro-inflammatory enzymes can be stimulated by LPS, an endotoxin component of gram-negative bacteria (14).

In this study, the selligueain A inhibition against the inflammatory mediator production was firstly examined by the toxicity test on the RAW264.7 cells using an MTS method. The test indicated no cell death caused by selligueain A at any concentration used.

Further testing was conducted on the inhibitory activity of selligueain A against the production of NO, iNOS, and TNF-α in LPS-induced RAW 264.7 cells. Inhibition of the production of these mediators is one of the targets to explore the mechanisms of action of anti-inflammatory drugs. Selligueain A at the concentrations of 100 and 150 µM inhibited NO production (indicated by the decrease in NO levels) was significantly different when compared to the control group. The inflammatory mediator NO is derived from the amino acid L-arginine by the iNOS enzyme. Drugs that can inhibit NO production can treat acute and chronic inflammatory symptoms (15,16).

In line with the inhibitory activity on NO production, the iNOS enzyme inhibition test was also carried out. Selligueain A at the concentrations of 100 and 150 µM reduced levels of iNOS enzyme protein, which was different from the control group. The RAW 264.7 cells, when induced by LPS, produced the iNOS enzyme to synthesize the inflammatory mediator NO.

Subsequent tests carried out on TNF-α showed that selligueain A at the concentration of 150 µM could significantly reduce the levels of TNF-α cytokines with the percentage inhibition value of 48.54%. TNF-α is a cytokine that can bind to receptors on the surface of target cells that play a role in ongoing inflammation. TNF-α can activate macrophages/monocytes, fibroblasts, mast cells, T cells, and natural killer cells. TNF-α can also trigger fever through stimulation of PGE2 synthesis in vascular endothelial cells and the hypothalamus. The continued presence of TNF-α has been reported to be responsible for a group of chronic inflammatory diseases such as parasitic infections, cancer, and rheumatoid arthritis (17). Overall data indicated that selligueain A was proven to reduce NO, iNOS, and TNF-α levels of RAW264.7 macrophage cells induced by LPS. These findings may be related to the anti-inflammatory mechanism of selligueain A, which was previously reported (4).

**Conclusion**

Selligueain A of the *P. feei* roots had anti-inflammatory activity through the inhibition of the production of inflammatory mediators, NO, iNOS, and TNF-α, the highest activity of which was shown by the concentration of 150 µM. These results increase scientific proof of the pharmacological activity of the *P. feei* roots.

**Authors’ contributions**

DWS made research designs, conducted all research experiments, compiled and processed data and wrote the scripts. TT assisted in conducting in vitro experiments and biomarker analysis. M supervised the extraction and isolation processes. AS directed the development of research designs and organized all stages of the experiment.

**Conflict of interests**

The authors declare no conflict of interest.

**Ethical considerations**

The experimental protocols were approved by the Research Ethics Committee of Faculty of Medicine, Universitas Padjadjaran, Indonesia, with the ethical clearance number of 325/UNG.KEP/EC/2019.

**Funding/Support**

Source of funding was the Ministry of Research and Technology and Higher Education, Jakarta, Indonesia. (Grant number: 1827/UN6.3.1/LT/2020).

**References**

1. Park SB, Park GH, Um Y, Kim HN, Song HM, Kim N, et al. Wood-cultivated ginseng exerts anti-inflammatory effect in LPS-stimulated RAW264.7 cells. Int J Biol Macromol. 2018;116:327-34. doi: 10.1016/j.ijbiomac.2018.05.039.

2. Damte D, Reza MA, Lee SJ, Jo WS, Park SC. Anti-inflammatory activity of dichloromethane extract of *Auricularia auricula-judae* in RAW264.7 cells. Toxicol Res. 2011;27(1):11-4. doi: 10.5487/tr.2011.27.1.011.

3. Afrin SR, Islam MR, Proma NM, Shorna MK, Akbar S, Hossain MK. Quantitative screening of phytochemicals and pharmacological attributes of the leaves and stem barks of *Macropanax dispermus* (Araliaceae) in treating the inflammation and arthritis. J Herbscreen Pharmacol. 2021;10(1):75-83. doi: 10.34172/jhp.2021.07.

4. Subarnas A, Wagner H. Analgesic and anti-inflammatory activity of the proanthocyanidin shellegueain A from *Polypodium feei* METT. Phytomedicine. 2000;7(5):401-5. doi: 10.1016/s0944-7113(00)80061-6.

5. Hasanah AN, Levita J, Natapoera ED, Subarnas A. Analyzing the interaction of shellegueain A: a bioactive compound of Pakis tangkur (*Selliguea feei* or *Polypodium macropanax*). Phytom. 2000;7(5):401-5.
Suwandi et al

(Sellowia feei) to cyclooxygenase enzyme by molecular docking. Asian J Chem. 2011;23(7):3093-6.

6. Baek NI, Chung MS, Shamon L, Kardono LB, Tsauri S, Padmawinata K, et al. Selligueain A, a novel highly sweet proanthocyanidin from the rhizomes of Selliguea feei. J Nat Prod. 1993;56(9):1532-8. doi: 10.1021/np50099a011.

7. Lee M, Shim SY, Sung SH. Triterpenoids isolated from Alnus japonica inhibited LPS-induced inflammatory mediators in HT-29 cells and RAW264.7 cells. Biol Pharm Bull. 2017;40(9):1544-50. doi: 10.1248/bpb.b16-00895.

8. McGowan EM, Alling N, Jackson EA, Yagoub D, Haass NK, Allen JD, et al. Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay. PLoS One. 2011;6(6):e20623. doi: 10.1371/journal.pone.0020623.

9. Lee CW, Kim SC, Kwak TW, Lee JR, Jo MJ, Ahn YT, et al. Anti-inflammatory effects of bangpungtongsung-san, a traditional herbal prescription. Evid Based Complement Alternat Med. 2012;2012:892943. doi: 10.1155/2012/892943.

10. Huang J, Qin Y, Liu B, Li GY, Ouyang L, Wang JH. In silico analysis and experimental validation of molecular mechanisms of salvianolic acid A-inhibited LPS-stimulated inflammation, in RAW264.7 macrophages. Cell Prolif. 2013;46(5):595-605. doi: 10.1111/cpr.12056.

11. Endrinaldi E, Darwin E, Zubir N, Revilla G. The effect of mesenchymal stem cell Wharton’s jelly on ADAMTS-4 and iNOS levels in osteoarthritis rat model. Open Access Maced J Med Sci. 2019;7(8):1270-5. doi: 10.3889/oamjms.2019.155.

12. Kim E, Yi YS, Son YJ, Han SY, Kim DH, Nam G, et al. BIOGF1K, a compound K-rich fraction of ginseng, plays an anti-inflammatory role by targeting an activator protein-1 signaling pathway in RAW264.7 macrophage-like cells. J Ginseng Res. 2018;42(2):233-7. doi: 10.1016/j.jgr.2018.02.001.

13. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, et al. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood. 2004;103(6):2229-37. doi: 10.1182/blood-2003-04-1356.

14. Pinho-Ribeiro FA, Verri WA Jr, Chiu IM. Nociceptor sensory neuron-immune interactions in pain and inflammation. Trends Immunol. 2017;38(1):5-19. doi: 10.1016/j.it.2016.10.001.

15. Millet P, Opiekun M, Martin T, Beauchamp GK, Kimball BA. Cytokine contributions to alterations of the volatile metabolome induced by inflammation. Brain Behav Immun. 2018;69:312-20. doi: 10.1016/j.bbi.2017.12.005.

16. Garcia R, Ferreira JP, Costa G, Santos T, Branco F, Caramona M, et al. Evaluation of anti-inflammatory and analgesic activities of Cymbopogon citratus in vivo-polyphenols contribution. Res J Med Plants. 2015;9(1):1-13. doi: 10.3923/rjmp.2015.1.13.

17. Wu J, Qu Y, Deng JX, Liang WY, Jiang ZL, Lai R, et al. Resveratrol inhibition of TNF-α and IL-1 for treatment of rheumatoid arthritis: from in-silico to in-vitro elucidation. Int J Clin Exp Med. 2016;9(2):745-52.